Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03198234
Other study ID # IRB-38734
Secondary ID PEDSBMT2975P01CA
Status Recruiting
Phase Phase 1
First received
Last updated
Start date August 30, 2017
Est. completion date July 2025

Study information

Verified date April 2023
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A significant number of patients with hematologic malignancies need a hematopoietic stem cell transplant (HSCT) to be cured. Only about 50% of these patients have a fully matched donor, the remaining patients will require an HSCT from a mismatched related or unrelated donor. Almost 60% of these mismatched donor HSCTs will result in graft-versus-host disease (GvHD), which can cause significant morbidity and increased non-relapse mortality. GvHD is caused by the donor effector T cells present in the HSC graft that recognize and react against the mismatched patient's tissues. Researchers and physicians at Lucile Packard Children's Hospital, Stanford are working to prevent GvHD after HSCT with a new clinical trial. The objective of this clinical program is to develop a cell therapy to prevent GvHD and induce graft tolerance in patients receiving mismatched unmanipulated donor HSCT. The cell therapy consists of a cell preparation from the same donor of the HSCT (T-allo10) containing T regulatory type 1 (Tr1) cells able to suppress allogenic (host-specific) responses, thus decreasing the incidence of GvHD. This is the first trial of its kind in pediatric patients and is only available at Lucile Packard Children's Hospital, Stanford. The purpose of this phase 1 study is to determine the safety and tolerability of a cell therapy, T-allo10, to prevent GvHD in patients receiving mismatched related or mismatched unrelated unmanipulated donor HSCT for hematologic malignancies.


Description:

Patients ages 3-30 years, with hematologic malignancies undergoing mismatched related or unrelated donor transplant will receive conditioning chemotherapy with Total body radiation and cyclophosphamide, according to the standard procedure. The investigators plan to infuse the donor T-allo10 product one day before HSCT so that the Tr1 cells contained within the T-allo10 product will be able to prevent anti-host alloreactivity of the T cells present within the unmanipulated HSC graft. Indeed, Tr1 cells best exert their suppressive activity at the time of effector T cell activation, occurring when the T cells present in the HSC graft will be transferred to the patient ; therefore, the investigators expect that the early infusion of T-allo10 cells will optimally modulate anti-host alloreactivity of the donor T cells and prevent GvHD. Immunosuppression will also be administered at the time of HSCT. Up to 27 eligible patients will be given the T-allo10 product sequentially in 3 escalating dose cohorts to determine the maximum tolerated dose (or the highest dose tested if no maximum tolerated dose is reached). Each cohort will begin by evaluating 3 patients. The patients in each cohort will be staggered by 28 days and each succeeding patient will be enrolled no sooner than the 29 day after the preceding patient's infusion of T-allo10. - If no patient in a cohort develops a dose limiting toxicity (DLT) following infusion of the investigational cellular product, the investigators will start enrolling patients at the next higher cell dose after completing the 28-day safety evaluation of the 3rd patient in the dose cohort. - If one out of 3 patients in a cohort has a DLT, 3 additional patients will be evaluated at the same dose level. - If one out of 6 patients experiences a DLT, dose escalation will occur. - If 2 out of ≤ 6 patients experience a DLT, dose escalation will cease and that dose will be designated the maximally administered dose. - Up to three (3) additional patients will be entered at the next lowest dose level if only 3 patients were treated previously at that dose


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date July 2025
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 3 Years to 45 Years
Eligibility Inclusion Criteria: 1. Eligible diseases include: A. Acute Lymphoblastic Leukemia (B- or T-ALL) 1. Complete Response (CR)1-ultra high risk features - Unfavorable cytogenetics - Hypodiploidy - Induction failure - Minimal Residual Disease (MRD) positive after consolidation 2. CR-2: - Any of the high risk features listed in CR1 - B-ALL: any relapse considered eligible for transplant - T- ALL 3. CR-3-any B. Acute Myeloid Leukemia 1. MRD >5% at day 22 induction 1 2. MRD >0.1% after induction 2 3. FLT/ITD with allelic ratio > 0.4 and MRD >0.1% at day 22 or 29 induction 1 4. Translocation (6:9), (8:6), (16:21), monosomy 7, monosomy 5, 5q 5. M7 with KMT2A rearrangements, inv(16)(p13.3q24.3) [CBFA2T3-GLIS2] or t(11;12)(p15;p13) [NUP98-KDM5A] 6. AML in 2nd or subsequent CR 7. Therapy related or Secondary AML 8. Refractory anemia with excess blasts (RAEB)2 C. Myelodysplastic syndrome D. Mixed Phenotype Acute Leukemia MRD>1% after consolidation E. Non-Hodgkin's lymphoma (NHL) or Hodgkin's lymphoma (HL) beyond first remission 2. Age =3 to =45 years old. Subjects 1 and 2 (in Cohort 1) will be = 12 years old 3. Available mismatched related donor (mMRD) or mismatched unrelated donor (mMUD), Human leukocyte antigen (HLA) matched 8/10 or 9/10 4. Lansky (age <16) or Karnofsky (age =16) performance status =80% 5. Able and willing to provide written, signed informed consent (assent as appropriate) 6. Have adequate organ function defined as the following: - Serum Creatinine <1.5 X upper limit of normal (ULN) or 24-hour creatinine clearance >50 ml/min - Serum bilirubin = 2 x ULN - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =10 x ULN - Diffusion Capacity of the Lungs (DLCO) >60% predicted (in children, O2 saturation >92% on room air) - Left ventricular ejection fraction >45% (in children, shortening fraction >26%) 7. Male and female subjects of child bearing potential must agree to use an effective method of birth control to avoid pregnancy throughout the transplant procedure, while on immunosuppression, and if the subject experiences any chronic GvHD. Exclusion Criteria: 1. Prior bone marrow or peripheral blood HSCT within the last 6 (six) months 2. HLA-matched related or unrelated donor available 3. Any active, uncontrolled infection at the time of enrollment 4. Pregnant or lactating females 5. Any severe concurrent disease which, in the judgement of the investigator, would place the patient at increased risk during participation in the study 6. Any subject with a history of significant renal, hepatic, pulmonary, or cardiac dysfunction or on treatment to support cardiac dysfunction 7. HIV positive 8. Non-cooperative behavior or non-compliance of the patient and/or of his/her family 9. Received another investigational agent within 30 days of enrollment 10. Patients with Down's syndrome

Study Design


Intervention

Biological:
T-allo10
The T-allo10 drug product consists of donor derived, host (patient) alloantigen hyporesponsive (anergic) CD4+ (cluster of differentiation 4) cells containing Type 1 regulatory T (Tr1) cells induced in vitro in the presence of IL-10 (interleukin-10), which are also defined as IL-10 anergized T cells. T-allo10 cell infusion is being developed to prevent acute Graft-versus-Host Disease (GvHD) and induce graft tolerance in patients with hematologic malignancies receiving mismatched related and unrelated unmanipulated hematopoietic stem cell transplant (HSCT).

Locations

Country Name City State
United States Lucile Packard Children's Hospital Palo Alto California

Sponsors (2)

Lead Sponsor Collaborator
Roncarolo, Maria Grazia, MD National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Incidence and severity of chronic GvHD The incidence and severity of chronic GvHD will be assessed by an independent evaluator. After Day +100 through Day +365,
Other Time to immune reconstitution Immune reconstitution will be evaluated by clinical laboratory studies of CD3+ T cells, assessed by the time to reach >200/microliter CD3+ T cells. Up to Day 365
Other Disease Free Survival Disease free survival is defined as the absence of minimal residual disease in the bone marrow.
The investigators will use bone marrow aspirate examination, minimal residual disease (MRD) assay, and donor chimerism by STR analysis to evaluate disease free survival.
At Day +365
Primary Incidence of treatment emergent adverse events (TEAE) Assessments of TEAE will include laboratory abnormalities, changes in vital signs, and changes in physical examination following infusion of T-allo10 cells in order to assess the tolerability of T-allo10. Time of T-allo10 cell infusion until 28 days following the infusion.
Primary Severity of treatment emergent adverse events (TEAE) Assessments of TEAE will include laboratory abnormalities, changes in vital signs, and changes in physical examination following infusion of T-allo10 cells in order to assess the safety of T-allo10. Time of T-allo10 cell infusion until 28 days following the infusion.
Primary Safety of T-allo10 will be measured by the time to stem cell engraftment after Hematopoietic Stem Cell Transplant. Stem cell engraftment is evaluated by clinical laboratory studies including absolute neutrophil count, hematopoiesis, chimerism analysis, and minimal residual disease (MRD) assay. 42 days
Primary Feasibility defined by the successful manufacture of the T-allo10 product Feasibility defined by the rate of successful manufacture of the T-allo10 product to satisfy the targeted dose level and meet the required release specifications. By Day -9
Secondary Incidence and severity of grade III and IV acute GvHD The incidence of grade III and IV acute GvHD at Day +100 following infusion of Tallo10 cells, assessed using the Modified Keystone scale administered by an independent evaluator on study visits through Day +100 Study visits through Day +100
See also
  Status Clinical Trial Phase
Terminated NCT03776864 - Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Phase 2
Recruiting NCT02356159 - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Phase 1/Phase 2
Terminated NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Phase 1
Terminated NCT01699581 - Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant Phase 2
Completed NCT00784537 - High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients Phase 2/Phase 3
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Recruiting NCT05355051 - A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma Phase 2
Completed NCT00520130 - Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System Phase 1/Phase 2
Withdrawn NCT01316146 - Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) Phase 1
Completed NCT02223052 - Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies Phase 1
Completed NCT02581007 - Reduced Intensity Conditioning Transplant Using Haploidentical Donors Phase 2
Terminated NCT01745913 - Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies Phase 2
Recruiting NCT04665063 - A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma N/A
Recruiting NCT02259556 - CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas Phase 1/Phase 2
Completed NCT02003625 - Meloxicam vs Placebo for Mobilization Phase 2
Terminated NCT01742793 - An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) Phase 1
Completed NCT01402687 - SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) N/A
Terminated NCT00901303 - Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma N/A
Completed NCT00283439 - A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma Phase 1/Phase 2
Completed NCT01272817 - Nonmyeloablative Allogeneic Transplant N/A